You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Loco-regional Recurrent Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PET on Surgery for Loco-regionally Recurrent Colorectal Cancer

Completed
  • PET-driven Surgery
  • Loco-regional Recurrent Colorectal Cancer
  • Curative intent surgery
  • Taipei, Taiwan
    National Taiwan University Hospital
Jul 2, 2023

Impact of Regional Anesthesia on Chronic Post-operative Pain

Enrolling by invitation
  • Breast Cancer
  • Milano, Lombardia, Italy
    ASST GOM Niguarda
May 16, 2023

Breastcancer, Mastectomy Trial in Lille (Loco-regional anaesthesia)

Completed
  • Breastcancer
  • Mastectomy
  • Loco-regional anaesthesia
  • Lille, France
    Centre Oscar Lambret
Nov 18, 2022

Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma Trial in Richmond, South Hill (External Beam Radiation

Active, not recruiting
  • Breast Cancer
  • +4 more
  • External Beam Radiation Therapy
  • +2 more
  • Richmond, Virginia
  • +1 more
Dec 16, 2022

Breast Cancer Trial in Shanghai (Regional lymph node radiotherapy, chest/whole breast irradiation)

Recruiting
  • Breast Cancer
  • Regional lymph node radiotherapy
  • chest/whole breast irradiation
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai jiaotong univestigy school of medicine
Aug 3, 2023

Lymphedema, Fibrosis Trial in Aarhus (Loco-regional RT)

Active, not recruiting
  • Lymphedema
  • Fibrosis
  • Loco-regional RT
  • Aarhus, Denmark
    Aarhus University Hospital
Jul 7, 2021

Cardiac Toxicity, Lung Cancer Stage III, Lung Cancer Stage II Trial in Odense C (Chemoradiotherapy)

Recruiting
  • Cardiac Toxicity
  • +4 more
  • Chemoradiotherapy
  • Odense C, Denmark
    Odense University Hospital
Feb 16, 2022

Recurrent Cancer, Prostate Cancer, Cervical Cancer Trial in Berlin (loco-regional hyperthermia)

Recruiting
  • Recurrent Cancer
  • +9 more
  • loco-regional hyperthermia
  • Berlin, Germany
    Klinik für Radioonkologie und Strahlentherapie
May 12, 2021

Breast Cancer Trial (SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 3, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

Breast Cancer, Recurrent Trial in Meldola (Partial breast re-irradiation)

Not yet recruiting
  • Breast Cancer
  • Recurrent
  • Partial breast re-irradiation
  • Meldola, Forlì Cesena, Italy
    UO Radioterapia, IRST IRCCS
Mar 6, 2023

Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 12, 2023

Breast Cancer, Breast Tumor, Breast Tumor Trial in United States (Proton Radiotherapy)

Active, not recruiting
  • Breast Cancer
  • +3 more
  • Proton Radiotherapy
  • Warrenville, Illinois
  • +4 more
Oct 24, 2021

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

Toxicities of Salvage Treatment in Locoregionally Recurrent

Not yet recruiting
  • Breast Cancer
  • Salvage treatment (surgery and/or radiation therapy)
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jul 5, 2023

Breast Cancer, Breast Cancer Recurrent Trial (rPBI)

Not yet recruiting
  • Breast Cancer
  • Breast Cancer Recurrent
  • rPBI
  • (no location specified)
Oct 21, 2022

HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)

Active, not recruiting
  • HER2-positive Breast Cancer
  • Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Jan 30, 2023

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)

Not yet recruiting
  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
  • (no location specified)
Apr 20, 2023

Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy Trial in Nanjing (Stained region

Recruiting
  • Axillary Lymph Node Dissection
  • +4 more
  • Stained region Lymph Node Biopsy (SrLNB)
  • Regional lymph node radiotherapy (RNI) including the axilla
  • Nanjing, China
    The First Affiliated Hospital of Nanjing Medical University
Jul 10, 2023

Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

Active, not recruiting
  • Edema
  • +8 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Jan 23, 2023

Breast Cancer Female, Breast Cancer Recurrent Trial in Drammen (18F-FDG PET/CT)

Recruiting
  • Breast Cancer Female
  • Breast Cancer Recurrent
  • 18F-FDG PET/CT
  • Drammen, Norway
    Drammen Hospital - Vestre Viken HF
Feb 17, 2023

Breast Cancer Trial in Prague, Haifa, Candiolo (drug, radiation, device)

Withdrawn
  • Breast Cancer
  • ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
  • +2 more
  • Prague, Czechia
  • +2 more
Mar 29, 2022

LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing

Not yet recruiting
  • Breast Cancer
    • (no location specified)
    Jan 9, 2023

    Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)

    Recruiting
    • Triple Negative Breast Cancer
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Sep 15, 2022